Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SLN vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: SLN 2 – 4 CGEN Matrix Metrics: SLN 4 – 6 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLN carries a Unified Composite Score of 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -11905.9% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Growth vs. Quality Trade-Off: CGEN earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. SLN 45.2/100 HOLD) and 1.44β · 62% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.9); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLN vs CGEN
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.80
+0.0% 1D
Market Cap $1.2B
TTM Revenue $456,000
Forward P/E N/M
Beta / 30D Vol 1.92β · 4% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 25.0 Fund 34.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.7% over 20 days), RSI 77
RSI-14: 76.9 · SMA20: $19.76 · SMA50: $14.89
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
47.1 / 100 HOLD
Tech 44.0 Fund 52.0 Flow 54.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (SLN 2 – 4 CGEN)

Columns: Metric · SLN · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue N/M 2.5x
2. Growth & Scale SLN
Revenue Growth (YoY) +197.2% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $456,000 $76M
Market Cap $1.2B $193.2M
3. Profitability & Quality CGEN
Gross Margin 95.0% 86.2%
Operating Margin -11905.9% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -35.6% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) -$54M EBITDA $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $3.46 Book/Sh · -35.6% ROE $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLN
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 55.4% (50th %ile) 89.7% (57th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLN (4) vs CGEN (6)
Institutional Metric SLN CGEN Criterion Row Edge
Market Capitalization
Scale
$1.2B $193.2M Larger Scale SLN
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
+197.2% +102.1% Higher Growth SLN
Operating Margin (TTM)
Profitability
-11905.9% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-35.6% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
100% ($4–$20) 33% ($1–$3) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.92β · 4% Vol 1.44β · 62% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 47.1 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
$456,000 $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
95.0% 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$54M EBITDA ($3.46 Book/Sh · -35.6% ROE) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGEN +1.42 pp
SLN: +1.12% · CGEN: +2.54%
3M Horizon SLN +62.69 pp
SLN: +45.48% · CGEN: -17.21%
6M Horizon SLN +269.16 pp
SLN: +243.15% · CGEN: -26.01%
1Y Horizon SLN +166.73 pp
SLN: +189.9% · CGEN: +23.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs CGEN. Trailing 12-month operating profitability (SLN -11905.9% vs CGEN 41.3%) and valuation multiples (SLN N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$456,000
Gross Margin95.0%
Op. Margin-11905.9%
ROE / Fwd P/E-35.6% · N/M
CGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin86.2%
Op. Margin41.3%
ROE / Fwd P/E57.2% · 12.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -11905.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ SLN vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over Silence Therapeutics Plc American Depository Share (SLN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLN carries a Unified Composite Score of 45.2/100 (HOLD) at $19.80 (N/M Forward P/E, -11905.9% operating margin), whereas CGEN carries 47.1/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Growth vs. Quality Trade-Off: CGEN earns the overall head-to-head edge with a stronger Unified Composite Score (47.1/100 HOLD vs. SLN 45.2/100 HOLD) and 1.44β · 62% Vol risk profile, whereas SLN leads top-line expansion (+197.2% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: SLN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 76.9); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SLN leads the Growth & Scale pillar: SLN posts +197.2% YoY revenue growth and +0.0% YoY earnings growth on $456,000 TTM revenue (95.0% gross margin, -11905.9% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). On trailing 12-month operating scale, SLN generates $456,000 in USD-normalized revenue versus $76M for CGEN. In operating R&D and SG&A reinvestment, SLN deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLN (-35.6% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.92β · 4% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.